Venrock joins the biotech VC fundraising game, tossing $447M into a $4.3B pot of new money
It’s not unusual to find the partners at Venrock traveling in the A-list section of biotech. They like to find some of the more mature startups headed toward IPOs or some new arrivals on the public market — sticking with deep-pocket investors looking to do big things. And they clearly have a big appetite for rounds that can range up into the stratosphere.
It looks like they’re going to remain in that neighborhood for some time to come.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 83,000+ biopharma pros reading Endpoints daily — and it's free.